Elan has not confirmed the payment. Photograph: Bryan O’Brien

Elan is reported to have paid more than $250,000 dollars to a former director after its board reported him to the Securities and Exchange Commission ((...)

While Royalty Pharma boosted its unsolicited offer to as much as $15.50 a share this month, at least five analysts covering Dublin-based Elan see the stock falling if that bid disappears

Elan shareholders risk losing $2 billion by listening to the company’s board and rejecting Royalty Pharma’s takeover bid, according to market analysts(...)

Former Elan board member Jack Schuler has questioned the experience  of the drug company’s management. Photo: Bloomberg

Elan has dismissed criticism from a former director who questioned the ability and competence of the board to transform itself into a royalties driven(...)